What question did this study set out to answer?

To compare the quality of life of Canadian renal transplant recipients treated with cyclosporine or tacrolimus.

February 11, 2026Journal of Nephrology

A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada

View Full Paper

Ask AI

Bookmark

To compare the quality of life of Canadian renal transplant recipients treated with cyclosporine or tacrolimus.
Included adult renal transplant recipients with graft function ≥18 months from 13 Canadian sites.
Stratified patients by calcineurin inhibitor received and matched by transplant center type.
Used SF-12 scale to assess physical and mental component scores.
Compared patient opinions on CNI-related side effects through categorical questions and a numerical Likert scale.
Employed chi-square test and ANOVA for statistical analysis.
Both treatment groups had similar physical (PCS) and mental (MCS) summary scores.
A higher percentage of tacrolimus recipients preferred to continue their treatment compared to cyclosporine recipients (67.4% vs. 44.4%).
More patients on cyclosporine expressed a wish to stop taking it compared to those on tacrolimus (23.4% vs. 2.3%).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Compares quality of life in renal transplant recipients treated with cyclosporine or tacrolimus, indicating no significant difference in QoL between the two groups.

Cite This Study

Prasad et al. (2010) studied this question.

synapsesocial.com/papers/698c1cc1267fb587c655f784 https://doi.org/10.1093/joneph/23.3.274

View Full Paper

Ask AI

Bookmark

Implication

Compares quality of life in renal transplant recipients treated with cyclosporine or tacrolimus, indicating no significant difference in QoL between the two groups.

A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada

Key Points

Discussion

Implication

Cite This Study

A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider